After more than 20 years developing its blood cancer immunotherapies, HaemaLogiX is preparing to kick off its IPO next week. Unless Trump’s Iran war gets in the way.
Hugo Mathers
Reporter
Hugo joined Capital Brief after five years in government roles across London and Sydney. He also previously worked in venture capital with Europe's first proptech VC fund Pi Labs and edtech startup Primo Toys, and has written for Time Out, Urban List and The Mandarin.
Contact Hugo via email.
The $4 trillion chipmaker’s strategy of investing in its own customers has been highly criticised, including by a prophet of the global financial crisis. Now it has come to Australia.
Even though both were criticised for selling down large amounts of stock earlier this year, their departure still spooked the market, wiping $500 million from Droneshield’s value.
The accounting software platform has teamed up with its would-be disruptor. Investors think other battered SaaS names could follow its lead.
The first big IPO at the ASX’s new headquarters in Martin Place was fittingly relaxed for a company best known for its mattresses. That didn’t stop the shares from soaring on debut.
The new listed investment trust is leaning into market turmoil with a $200m float, pitching itself as a “safe harbour” as investors hunt for defensive opportunities.
The medical imaging company has experienced a run for the ages, with the stock up 2,000% in the ASX in less than a year. Not everyone is convinced it can continue.
